|
07/07/2024 |
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
|
Pau Abrisqueta |
Eva González-Barca, MD PhD, Christelle M Ferra, Eduardo Ríos Herranz, MD, Margarita Fernández, MD, Julio Delgado, MD, Rafael Andreu, MD, José Ángel Hernández-Rivas, MD PhD, María José Terol, Marcos González, Patricia Baltasar Tello, MD, Javier de la Serna, MD PhD, Ángel Ramírez Payer, Carmen Ballester, MD, Carol Moreno, MD PhD, José A. García-Marco, MD PhD, Raúl Córdoba, MD PhD, Lucrecia Yáñez San Segundo, MD PhD, Luis Felipe Casado Montero, MD, Francesc Bosch, MD PhD. |
Blood - ASH |
21.0 |
Ver artículo
|
|
06/05/2023 |
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study
|
Julio Bravo |
Julio Bravo, Patricia Baltasar Tello, Esther González Garcia, Eduardo Ríos Herranz, Angel Ramirez Páyer, María José Terol Castera, Diana Champ, Angeles Medina Perez, Mercedes Gironella, Miguel Fernández Zarzoso, Rafael Forés, Julio Delgado, José A Garcia-Marco; GABRIELL Study Group/Investigators |
Leukemia & Lymphoma |
2.2 |
Ver artículo
|
|
03/10/2021 |
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
|
Julia González-Rincón |
José A Garcia-Vela, Sagrario Gómez, Belén Fernández-Cuevas, Sara Nova-Gurumeta, Nuria Pérez-Sanz, Miguel Alcoceba, Marcos González, Eduardo Anguita, Javier López-Jiménez, Eva González-Barca, Lucrecia Yáñez, Ernesto Pérez-Persona, Javier de la Serna, Miguel Fernández-Zarzoso, Guillermo Deben, Francisco J Peñalver, María C Fernández, Jaime Pérez de Oteyza, M Ángeles Andreu, M Ángeles Ruíz-Guinaldo, Raquel Paz-Arias, M Dolores García-Malo, Valle Recasens, Rosa Collado, Raúl Córdoba, Belén Navarro-Matilla, Margarita Sánchez-Beato, José A García-Marco |
Plos One Journal |
- |
Ver artículo
|
|
07/11/2019 |
Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
|
Pau Abrisqueta |
Eva González-Barca, MD PhD, Christelle M Ferra, Eduardo Ríos Herranz, MD, Margarita Fernández, MD, Julio Delgado, MD, Rafael Andreu, MD, José Ángel Hernández-Rivas, MD PhD, María José Terol, Marcos González, Patricia Baltasar Tello, MD, Javier de la Serna, MD PhD, Ángel Ramírez Payer, Carmen Ballester, MD, Carol Moreno, MD PhD, José A. García-Marco, MD PhD, Raúl Córdoba, MD PhD, Lucrecia Yáñez San Segundo, MD PhD, Luis Felipe Casado Montero, MD, Francesc Bosch, MD PhD. |
Blood - ASH |
21.0 |
Ver artículo
|
|
01/04/2017 |
Actualización de las guías nacionales de consenso del Grupo Espanol de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónicaActualización de las guías nacionales de consenso del Grupo Espanol de Leucemia Linfocí
|
José A. García Marco |
Julio Delgado, José A. Hernández-Rivas, Ángel Ramírez Payer, Javier Loscertales Pueyo, Isidro Jarque, Pau Abrisqueta, Pilar Giraldo, Rafael Martínez, Lucrecia Yánez, Ma José Terol, Marcos González y Francesc Bosch, en nombre del Grupo Español de Leucemia |
Sciencedirect - Elsevier |
2.6 |
Ver artículo
|
|
05/12/2016 |
Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)
|
Anna Maria Fink, MD |
Anna Maria Fink, MD, Jasmin Bahlo, PhD, Robrecht Sandra, PhD, Othman Al-Sawaf, MD, Ali Aldaoud, MD, Holger Hebart, MD, Kathleen Jentsch-Ulrich, MD, Steffen Doerfel, Dipl.MD, Kirsten Fischer, Clemens Martin Wendtner, MD, Thomas Noesslinger, MD, Paolo Ghia, MD PhD, Francesc Bosch, MD PhD, Arnon P. Kater, MD PhD, Karl-Anton Kreuzer, Hartmut Dohner, MD, Michael Kneba, Stephan Stilgenbauer, Sebastian Boettcher, MD, Barbara Eichhorst, MD, Michael Hallek, MD |
Blood - ASH |
21.0 |
Ver artículo
|
|
04/05/2016 |
The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)
|
P Montesinos |
M Cabrero, D Valcárcel, M Rovira, J A García-Marco, J Loscertales, C Moreno, R Duarte, M J Terol, N Villamor, P Abrisqueta, D Caballero, J Sanz, J Delgado |
Bone Marrow Transplantation - Nature |
4.5 |
Ver artículo
|
|
02/12/2013 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
|
Pau Abrisqueta |
Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. García-Marco, Yolanda González, Felix Carbonell, Secundino Ferrer, Encarna Monzó, Isidro Jarque, Ana Muntañola, Mireia Constants |
Blood - ASH |
21.1 |
Ver artículo
|
|
01/07/2013 |
Guía de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocítica crónicaNational guidelines for the management of patients with chronic lymphocytic leukemia
|
José A. García Marco |
Pilar Giraldo Castellano, Javier López Jiménez, Eduardo Ríos Herranz, José Luis Sastre Moral, M. José Terol Casterá, Francesc Bosch Albareda, en representación del Grupo Español de Leucemia Linfática Crónica (GELLC) |
Sciencedirect - Elsevier |
2.6 |
Ver artículo
|
|
02/11/2011 |
Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study
|
Pau Abrisqueta |
Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. García-Marco, Yolanda González, Felix Carbonell, Secundino Ferrer, Encarna Monzó, Isidro Jarque, Ana Muntañola, Mireia Constants, Lourdes Escoda, Xavier Calvo, Sabela Bobillo, José Bruno Montoro, Emili Montserrat, Francesc Bosch |
Blood - ASH |
21.0 |
Ver artículo
|
|
03/11/2010 |
Rituximab maintenance after combined FCR in previously untreated patients with active b-cell CLL: interim analysis of an ongoing phase ii multicenter trial on behalf of the spanish CLL study group (GELLC)
|
J. Garcia-Marco |
Jose A Garcia-Marco, MD, PhD, Javier Lopez-Jimenez, MD, Secundino Ferrer, MD, Pilar Giraldo, MD, PhD, Eva González-Barca, MD, Belen Navarro, MD, Eulogio Conde, MD, PhD, Marcos González, Jose L. Guzman, MD, Ernesto Perez, MD, Javier De la Serna, MD, PhD, Mar Osma, MD, Guillermo Deben, MD, Encarna Monzo, MD, Raquel de Paz, MD, M. Angeles Ruiz, MD, Francisco-Javier Penalver, Isidro Jarque, MD, Helena Bañas, MD, M. Carmen Fernandez, MD, Rafael Martinez, MD, Carmen Burgaleta, MD, Jaime Perez de Oteiza, MD, M.Angeles Andreu, MD, Ana Carral, MD, Inmaculada Fuentes, MD, Eva Donato, MD, Paola Leon, MD, Felix Carbonell, MD, Jose A. Garcia-Vela, MD |
Blood - ASH |
21.0 |
Ver artículo
|
|
24/08/2009 |
Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic LeukemiaRituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chr
|
Pau Abrisqueta |
Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. García-Marco, Yolanda González, Felix Carbonell, Secundino Ferrer, Encarna Monzó, Isidro Jarque, Ana Muntañola, Mireia Constants, Lourdes Escoda, Xavier Calvo, Sabela Bobillo, José Bruno Montoro, Emili Montserrat, Francesc Bosch |
JCO |
42.1 |
Ver artículo
|
